Show simple item record

FieldValueLanguage
dc.contributor.authorBurton, C
dc.contributor.authorAzzi, A
dc.contributor.authorKerridge, I
dc.date.accessioned2014-06-23
dc.date.available2014-06-23
dc.date.issued2002-01-01
dc.identifier.citationBurton C, Azzi A, Kerridge I H. Bone marrow necrosis following treatment for chronic myeloid leukaemia with STI-571. N Engl J Med; 2002; 346(9):713.en_AU
dc.identifier.urihttp://hdl.handle.net/2123/10811
dc.description.abstractImatinib mesylate has recently been licensed for the treatment of selected patients with chronic myelogenous leukemia (CML). 1We report a case of bone marrow necrosis secondary to imatinib mesylate therapy in a patient with accelerated-phase CMLen_AU
dc.language.isoen_AUen_AU
dc.publisherMassachusetts Medical Societyen_AU
dc.titleBone marrow necrosis following treatment for chronic myeloid leukaemia with STI-571en_AU
dc.typeArticle, Letteren_AU
dc.type.pubtypePublisher versionen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.